Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegolsihematide
- Development stage
- Unknown
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Subcutaneous
01
Overview
Pegolsihematide (HS-10370) is a long-acting, synthetic, PEGylated erythropoietin receptor agonist peptide developed by Jiangsu Hansoh Pharmaceutical. It is designed to treat anemia in patients with chronic kidney disease (CKD), particularly those on dialysis. Unlike traditional erythropoiesis-stimulating agents (ESAs) which are typically recombinant proteins, pegolsihematide is a peptide-based molecule that mimics the biological activity of erythropoietin by binding to and activating the erythropoietin receptor. The addition of a polyethylene glycol (PEG) moiety extends the drug's half-life, allowing for a reduced dosing frequency, typically once every four weeks. It received marketing approval from China's National Medical Products Administration (NMPA) in June 2023.
- Brand names
- Saint-A
- Other names
- pegolsihematide
02
Targets
Erythropoietin Receptor
Beyond the preview
Go deeper on pegolsihematide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegolsihematide.